Compass Therapeutics annual working capital
2019
2020
2020
2021
2022
2023
2024
2025
Compass Therapeutics Working Capital Growth & History (CMPX)
Compass Therapeutics's working capital was $195.9M for fiscal 2025.
View full Compass Therapeutics company overviewCompass Therapeutics annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $195.9M | $72.0M | +58.10% |
| 2024 | 2024-12-31 | $123.9M | −$22.2M | −15.20% |
| 2023 | 2023-12-31 | $146.1M | −$32.5M | −18.22% |
| 2022 | 2022-12-31 | $178.6M | $42.1M | +30.88% |
| 2021 | 2021-12-31 | $136.5M | $96.4M | +240.31% |
| 2020 · Dec 31 | 2020-12-31 | $40.1M | — | — |
| 2020 · Mar 31 | 2020-03-31 | −$108,072 | −$37,483 | — |
| 2019 · Mar 31 | 2019-03-31 | −$70,589 | — | — |
Compass Therapeutics quarterly working capital
As of Mar 31, 2018
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q4.19
Q4.20
Q1.21
Q2.21
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $164.8M | $72.4M | +78.44% |
| Q1 2026 | 2026-03-31 | $185.4M | $76.2M | +69.72% |
| Q4 2025 | 2025-12-31 | $195.9M | $72.0M | +58.10% |
| Q3 2025 | 2025-09-30 | $208.7M | $72.0M | +52.67% |
| Q2 2025 | 2025-06-30 | $92.3M | −$51.7M | −35.89% |
| Q1 2025 | 2025-03-31 | $109.2M | −$45.5M | −29.39% |
| Q4 2024 | 2024-12-31 | $123.9M | −$22.2M | −15.20% |
| Q3 2024 | 2024-09-30 | $136.7M | −$20.8M | −13.18% |
| Q2 2024 | 2024-06-30 | $144.0M | −$21.5M | −13.01% |
| Q1 2024 | 2024-03-31 | $154.7M | −$17.7M | −10.26% |
| Q4 2023 | 2023-12-31 | $146.1M | −$32.5M | −18.22% |
| Q3 2023 | 2023-09-30 | $157.5M | $44.5M | +39.37% |
| Q2 2023 | 2023-06-30 | $165.6M | $41.9M | +33.89% |
| Q1 2023 | 2023-03-31 | $172.4M | $41.5M | +31.66% |
| Q4 2022 | 2022-12-31 | $178.6M | $42.1M | +30.88% |
| Q3 2022 | 2022-09-30 | $113.0M | $92.1M | +440.84% |
| Q2 2022 | 2022-06-30 | $123.7M | $97.5M | +373.05% |
| Q1 2022 | 2022-03-31 | $130.9M | $100.2M | +325.20% |
| Q4 2021 | 2021-12-31 | $136.5M | $96.4M | +240.31% |
| Q3 2021 | 2021-09-30 | $20.9M | −$27.3M | −56.62% |
| Q2 2021 · Jun 30 | 2021-06-30 | $26.1M | −$29.5M | −53.05% |
| Q1 2021 · Mar 31 | 2021-03-31 | $30.8M | $30.9M | — |
| Q4 2020 · Dec 31 | 2020-12-31 | $40.1M | $49.9M | — |
| Q2 2021 · Sep 30 | 2020-09-30 | $48.2M | $48.2M | — |
| Q1 2021 · Jun 30 | 2020-06-30 | $55.7M | $55.8M | — |
| Q4 2020 · Mar 31 | 2020-03-31 | −$108,072 | −$37,483 | — |
| Q4 2019 · Dec 31 | 2019-12-31 | −$9.8M | −$9.8M | — |
| Q2 2020 | 2019-09-30 | −$90,454 | −$38,872 | — |
| Q1 2020 | 2019-06-30 | −$82,051 | −$39,025 | — |
| Q4 2019 · Mar 31 | 2019-03-31 | −$70,589 | −$36,037 | — |
| Q3 2019 | 2018-12-31 | −$61,724 | — | — |
| Q2 2019 | 2018-09-30 | −$51,582 | — | — |
| Q1 2019 | 2018-06-30 | −$43,026 | — | — |
| As of Mar 31, 2018 | 2018-03-31 | −$34,552 | — | — |
Compass Therapeutics working capital trends
Over the last five fiscal years, Compass Therapeutics's working capital increased from $40.1M to $195.9M, a change of $155.7M. The latest reported quarter, Q2 2026, shows $164.8M.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Compass Therapeutics source filings ↗